Medical Facilities (DR) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
25 Nov, 2025Executive summary
First quarter performance matched the strong prior year, with facility service revenue at $81.7 million, despite economic uncertainty and one less surgical day due to the leap year comparison.
Surgical case volumes increased 2.2% year-over-year, with observation and outpatient cases up 6.8% and 4.8% respectively.
EBITDA rose 0.7% year-over-year to $17.3 million.
Income from operations was $13 million, unchanged from the prior year.
$44.3 million was returned to shareholders via substantial issuer bid and share repurchases, reducing share count by 14.7%.
Financial highlights
Facility service revenue was $81.7 million, flat compared to the same quarter last year.
Net income from continuing operations increased 89.1% to $9 million year-over-year.
Basic and diluted EPS were $0.17, up from $(0.01) in Q1 2024.
Operating expenses before non-cash items were $68.5 million, nearly unchanged year-over-year.
Distributable cash flow (C$) was $9.1 million, down 4.4% year-over-year.
Outlook and guidance
No structural issues identified at Oklahoma Surgical Hospital; revenue decline attributed to timing and case mix, not expected to be a trend.
Capital allocation priorities include continued share repurchases and reinvestment in existing facilities; special dividend remains a last resort.
No acquisitions planned; focus remains on operational enhancements and efficiency.
Latest events from Medical Facilities
- Strong revenue and earnings growth, major asset sales, and buybacks boosted shareholder returns.DR
Q4 202512 Mar 2026 - Revenue and EBITDA rose on strong case volumes; PPP loan forgiveness to boost Q3.DR
Q2 20242 Feb 2026 - Q3 net income up 263% and revenue up 11.2%, driven by PPP loan forgiveness and case growth.DR
Q3 202416 Jan 2026 - Net income nearly doubled in 2024, fueled by asset sales and robust capital returns.DR
Q4 202426 Dec 2025 - Q2 saw SFSH headwinds but strong net income growth and new $40M credit secured.DR
Q2 202523 Nov 2025 - 7.5% revenue growth, 10.2% higher EBITDA, and $5.6M in share buybacks in Q3 2025.DR
Q3 202513 Nov 2025